The DEA dose not take these findings lightly and is rumored to be considering re evaluating their initial thoughts of a Schedule IV, hence the delay:
Events of euphoria, hallucination, and dissociation were seen with BELVIQ at supratherapeutic doses in shortterm studies [see Adverse Reactions (6.1), Drug Abuse and Dependence (9.2), and Overdosage (10)]. In clinical trials of at least 1-year in duration, 6 patients (0.2%) treated with BELVIQ developed euphoria, as compared with 1 patient (
PM: Wow 6 patients! Please characterize the euphoria further---was it mild moderate or severe in these patients, were the events transient.? Can you please tell us what other drugs these 6 patients were taking at the time and comment on potential drug interactions that could lead to the events. Can you tell us how the doctors (investigators) of these patient scored the potential for these events to be related to belviq (the study medication at the time).
Your full of something and its not knowledge--you know just enough to sound like you know something---you dont.
These 6 adverse events reported are no justification to schedulle this drug as a Class 3. This drug was tested in multiple thousands of patients---six? They are minor findings reflected in language in the drugs label. Your just blowing smoke and trying to create doubt! Your trying to make this drug sound like some kind of special mushrooms found in the woods!
Your view of belviq is more personal euphoria than these 6 events! Your premise is a long term adverse event of your taking Qysmia!